Clinical Trial Update: A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease [Phase 2]

View source ↗

Summary

Novartis conducted a Phase 2 trial comparing ECF843 to vehicle in subjects with dry eye disease. The study is completed and results were posted on May 26, 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• ECF843

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dry Eye | Phase 2 | Status: COMPLETED | Results posted: 2022-05-26